364 related articles for article (PubMed ID: 28173960)
1. Exploratory efficacy endpoints in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA).
Webber C; Patton M; Patterson S; Schmoele-Thoma B; Huijts SM; Bonten MJ;
Vaccine; 2017 Mar; 35(9):1266-1272. PubMed ID: 28173960
[TBL] [Abstract][Full Text] [Related]
2. A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands.
Gessner BD; Jiang Q; Van Werkhoven CH; Sings HL; Webber C; Scott D; Gruber WC; Grobbee DE; Bonten MJM; Jodar L
Vaccine; 2019 Jul; 37(30):4147-4154. PubMed ID: 31155413
[TBL] [Abstract][Full Text] [Related]
3. Post-hoc analysis of a randomized controlled trial: Diabetes mellitus modifies the efficacy of the 13-valent pneumococcal conjugate vaccine in elderly.
Huijts SM; van Werkhoven CH; Bolkenbaas M; Grobbee DE; Bonten MJM
Vaccine; 2017 Aug; 35(34):4444-4449. PubMed ID: 28410813
[TBL] [Abstract][Full Text] [Related]
4. Prevention of adult pneumococcal pneumonia with the 13-valent pneumococcal conjugate vaccine: CAPiTA, the community-acquired pneumonia immunization trial in adults.
Isturiz R; Webber C
Hum Vaccin Immunother; 2015; 11(7):1825-7. PubMed ID: 26076136
[TBL] [Abstract][Full Text] [Related]
5. Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults.
Suaya JA; Jiang Q; Scott DA; Gruber WC; Webber C; Schmoele-Thoma B; Hall-Murray CK; Jodar L; Isturiz RE
Vaccine; 2018 Mar; 36(11):1477-1483. PubMed ID: 29429807
[TBL] [Abstract][Full Text] [Related]
6. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.
Bonten MJ; Huijts SM; Bolkenbaas M; Webber C; Patterson S; Gault S; van Werkhoven CH; van Deursen AM; Sanders EA; Verheij TJ; Patton M; McDonough A; Moradoghli-Haftvani A; Smith H; Mellelieu T; Pride MW; Crowther G; Schmoele-Thoma B; Scott DA; Jansen KU; Lobatto R; Oosterman B; Visser N; Caspers E; Smorenburg A; Emini EA; Gruber WC; Grobbee DE
N Engl J Med; 2015 Mar; 372(12):1114-25. PubMed ID: 25785969
[TBL] [Abstract][Full Text] [Related]
7. The Community-Acquired Pneumonia immunization Trial in Adults (CAPiTA): what is the future of pneumococcal conjugate vaccination in elderly?
van Werkhoven CH; Bonten MJ
Future Microbiol; 2015; 10(9):1405-13. PubMed ID: 26347153
[TBL] [Abstract][Full Text] [Related]
8. Effects of 13-valent pneumococcal conjugate vaccination of adults on lower respiratory tract infections and antibiotic use in primary care: secondary analysis of a double-blind randomized placebo-controlled study.
van Werkhoven CH; Bolkenbaas M; Huijts SM; Verheij TJM; Bonten MJM
Clin Microbiol Infect; 2021 Jul; 27(7):995-999. PubMed ID: 32971253
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease among children in the United States between 2010 and 2019: An indirect cohort study.
Andrejko KL; Gierke R; Rowlands JV; Rosen JB; Thomas A; Landis ZQ; Rosales M; Petit S; Schaffner W; Holtzman C; Barnes M; Farley MM; Harrison LH; McGee L; Chochua S; Verani JR; Cohen AL; Pilishvili T; Kobayashi M
Vaccine; 2024 Jun; 42(16):3555-3563. PubMed ID: 38704263
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of an 11-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia among children less than 2 years of age in the Philippines: a randomized, double-blind, placebo-controlled trial.
Lucero MG; Nohynek H; Williams G; Tallo V; Simões EA; Lupisan S; Sanvictores D; Forsyth S; Puumalainen T; Ugpo J; Lechago M; de Campo M; Abucejo-Ladesma E; Sombrero L; Nissinen A; Soininen A; Ruutu P; Riley I; Mäkelä HP
Pediatr Infect Dis J; 2009 Jun; 28(6):455-62. PubMed ID: 19483514
[TBL] [Abstract][Full Text] [Related]
11. Pneumococcal conjugate vaccine use for the prevention of pneumococcal disease in adults <50 years of age.
Isturiz RE; Hall-Murray C; McLaughlin JM; Snow V; Schmoele-Thoma B; Webber C; Thompson A; Scott DA
Expert Rev Vaccines; 2018 Jan; 17(1):45-55. PubMed ID: 29183235
[TBL] [Abstract][Full Text] [Related]
12. Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: A systematic review and pooled analysis.
McLaughlin JM; Jiang Q; Gessner BD; Swerdlow DL; Sings HL; Isturiz RE; Jodar L
Vaccine; 2019 Oct; 37(43):6310-6316. PubMed ID: 31522807
[TBL] [Abstract][Full Text] [Related]
13. The impact of 13-valent pneumococcal conjugate vaccination on virus-associated community-acquired pneumonia in elderly: Exploratory analysis of the CAPiTA trial.
Huijts SM; Coenjaerts FEJ; Bolkenbaas M; van Werkhoven CH; Grobbee DE; Bonten MJM;
Clin Microbiol Infect; 2018 Jul; 24(7):764-770. PubMed ID: 29050992
[TBL] [Abstract][Full Text] [Related]
14. A public health evaluation of 13-valent pneumococcal conjugate vaccine impact on adult disease outcomes from a randomized clinical trial in the Netherlands.
Gessner BD; Jiang Q; Van Werkhoven CH; Sings HL; Webber C; Scott D; Neuzil KM; O'Brien KL; Wunderink RG; Grobbee DE; Bonten MJM; Jodar L
Vaccine; 2019 Sep; 37(38):5777-5787. PubMed ID: 29861177
[TBL] [Abstract][Full Text] [Related]
15. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
[TBL] [Abstract][Full Text] [Related]
16. Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN).
LeBlanc JJ; ElSherif M; Ye L; MacKinnon-Cameron D; Ambrose A; Hatchette TF; Lang ALS; Gillis HD; Martin I; Demczuk W; Andrew MK; Boivin G; Bowie W; Green K; Johnstone J; Loeb M; McCarthy AE; McGeer A; Semret M; Trottier S; Valiquette L; Webster D; McNeil SA
Vaccine; 2019 Aug; 37(36):5466-5473. PubMed ID: 31345638
[TBL] [Abstract][Full Text] [Related]
17. 13-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults.
Plosker GL
Drugs; 2015 Sep; 75(13):1535-46. PubMed ID: 26242768
[TBL] [Abstract][Full Text] [Related]
18. A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults.
Chalmers JD; Campling J; Dicker A; Woodhead M; Madhava H
BMC Pulm Med; 2016 May; 16(1):77. PubMed ID: 27169895
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design.
McLaughlin JM; Jiang Q; Isturiz RE; Sings HL; Swerdlow DL; Gessner BD; Carrico RM; Peyrani P; Wiemken TL; Mattingly WA; Ramirez JA; Jodar L
Clin Infect Dis; 2018 Oct; 67(10):1498-1506. PubMed ID: 29790925
[TBL] [Abstract][Full Text] [Related]
20. Pneumococcal conjugate vaccine herd effects on non-invasive pneumococcal pneumonia in elderly.
van Werkhoven CH; Hollingsworth RC; Huijts SM; Bolkenbaas M; Webber C; Patterson S; Sanders EA; Bonten MJ
Vaccine; 2016 Jun; 34(28):3275-82. PubMed ID: 27171754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
